Georg Dietrich

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller et al. · The Lancet Oncology · 2015 · 251 citations

Medicine, Oncology, Pharmacology +12

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Wolff Schmiegel, A. Reinacher-Schick, Dirk Arnold et al. · Annals of Oncology · 2013 · 73 citations

Medicine, Oncology, Pharmacology +13

Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

G. Hartung, R. D. Hofheinz, Y. Dencausse et al. · Oncology Research and Treatment · 2005 · 64 citations

Medicine, Oncology, Pharmacology +17

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Axel Grothey, Kim Jordan, O Kellner et al. · European Journal of Cancer Supplements · 2003 · 63 citations

Medicine, Oncology, Pharmacology +14

Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and discharge letter information

Mathias Kaspar, Georg Fette, Gülmisal Güder et al. · Clinical Research in Cardiology · 2018 · 56 citations · Full text

Computing, Biomedical Informatics, Health Informatics +16